| Literature DB >> 26138514 |
Sadakatsu Ikeda1, Donna E Hansel2, Razelle Kurzrock3.
Abstract
Advanced urothelial carcinoma is frequently lethal, and improvements in cytotoxic chemotherapy have plateaued. Recent technological advances allows for a comprehensive analysis of genomic alterations in a timely manner. The Cancer Genome Atlas (TCGA) study revealed that there are numerous genomic aberrations in muscle-invasive urothelial carcinoma, such as TP53, ARID1A, PIK3CA, ERCC2, FGFR3, and HER2. Molecular targeted therapies against similar genetic alterations are currently available for other malignancies, but their efficacy in urothelial carcinoma has not been established. This review describes the genomic landscape of malignant urothelial carcinomas, with an emphasis on the potential to prosecute these tumours by deploying novel targeted agents and immunotherapy in appropriately selected patient populations.Entities:
Keywords: Genetic aberrations; Immune therapy; Targeted therapy; Urothelial carcinoma
Mesh：
Substances：
Year: 2015 PMID： 26138514 DOI： 10.1016/j.ctrv.2015.06.004
Source DB: PubMed Journal: Cancer Treat Rev ISSN： 0305-7372 Impact factor: 12.111